Cellerant adds two new management components
This article was originally published in Scrip
Cellerant Therapeutics, a biotechnology company which specialises in therapies for blood disorders, has appointed Dr Margaret Dillon as vice president of regulatory affairs and Dr Robert Tressler as vice president of research and development. Dr Dillon comes to Cellerant with 19 years of experience in pharmaceutical regulatory affairs, most recently with CV Therapeutics (now Gilead Sciences). Dr Tressler brings to the table 20 years of industry experience in oncology, cardiovascular and immunological indications. Most recently, he served as executive director of research for Geron.
You may also be interested in...
Los Angeles-based Response Genetics, a company developing and commercialising molecular diagnostic tests for cancer has appointed Christine Meda as the new company president. Ms Meda brings nearly 30 years of know-how in strategic partnering, operations, and marketing to her role at Response. She also founded and is still president of RxDxLink, a consultancy advising early stage biotechnology firms.